JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB49854

Anti-Cathepsin G 抗体

Anti-Cathepsin G antibody

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Polyclonal Cathepsin G antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human Cathepsin G.

別名を表示する

Cathepsin G, CG, CTSG

1 Images
Western blot - Anti-Cathepsin G antibody (AB49854)
  • WB

Unknown

Western blot - Anti-Cathepsin G antibody (AB49854)

All lanes:

Western blot - Anti-Cathepsin G antibody (ab49854) at 1/1000 dilution

Lane 1:

Human Cathepsin G at 0.01 µg

Lane 2:

Human Cathepsin G at 0.005 µg

Lane 3:

Human Cathepsin G at 0.002 µg

Predicted band size: 28 kDa

Observed band size: 24 kDa,25 kDa,29 kDa

false

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB

applications

免疫原

Synthetic Peptide within Human Cathepsin G. The exact immunogen used to generate this antibody is proprietary information.

P08311

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "<p></p>" } } }

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Immunogen
バッファー組成
pH: 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 2.9% Sodium chloride
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
保管に関する情報
Stable for 12 months at -20°C

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Cathepsin G also known as CTSG is a serine protease with a molecular mass of approximately 29 kDa. It is primarily located in azurophilic granules of neutrophils a type of white blood cell. Cathepsin G functions mechanically as an enzyme cleaving peptide bonds in proteins and shaping the protein components involved in various immune responses. Its enzymatic activity is important for host defense processes including bacterial degradation and immune cell signaling. Researchers easily measure and study 'G activity' using specific functional assays.
Biological function summary

Cathepsin G plays a significant role in the immune system by contributing to inflammatory responses and regulating cellular processes through its proteolytic activity. It participates in activating other proteins such as anti-bacterial serine enzymes and breaking down extracellular matrix components during immune response facilitation. While not part of a larger complex cathepsin G works alongside other proteases showing combinatory effects in innate immunity.

Pathways

Cathepsin G is involved in the immune and inflammatory pathways. It plays a part in the regulation of inflammatory responses and contributes to the activation of cytokines during infection and tissue injury. Cathepsin G connects through shared activity with other proteases like neutrophil elastase influencing processes in tissue remodeling and cytokine release. It sustains immune system homeostasis maintaining a balance between inflammation and tissue repair in these pathways.

Cathepsin G is linked to chronic inflammatory conditions and autoimmune disorders. For example rheumatoid arthritis showcases the enzyme's connection where cathepsin G contributes to tissue damage and joint inflammation. Cathepsin G's increased activity associates with neutrophil elastase aggravating symptoms of chronic obstructive pulmonary disease (COPD) as it contributes to lung tissue degradation. Understanding cathepsin G's role in these diseases aids research in therapeutic target development focusing on 'E-64d' inhibitors. These inhibitors reduce inflammatory damage by curbing excessive protease activity.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Serine protease with trypsin- and chymotrypsin-like specificity (PubMed : 29652924, PubMed : 8194606). Also displays antibacterial activity against Gram-negative and Gram-positive bacteria independent of its protease activity (PubMed : 2116408, PubMed : 2117044). Prefers Phe and Tyr residues in the P1 position of substrates but also cleaves efficiently after Trp and Leu (PubMed : 29652924). Shows a preference for negatively charged amino acids in the P2' position and for aliphatic amino acids both upstream and downstream of the cleavage site (PubMed : 29652924). Required for recruitment and activation of platelets which is mediated by the F2RL3/PAR4 platelet receptor (PubMed : 10702240, PubMed : 3390156). Binds reversibly to and stimulates B cells and CD4(+) and CD8(+) T cells (PubMed : 7842483, PubMed : 9000539). Also binds reversibly to natural killer (NK) cells and enhances NK cell cytotoxicity through its protease activity (PubMed : 9000539, PubMed : 9536127). Cleaves complement C3 (PubMed : 1861080). Cleaves vimentin (By similarity). Cleaves thrombin receptor F2R/PAR1 and acts as either an agonist or an inhibitor, depending on the F2R cleavage site (PubMed : 10702240, PubMed : 7744748). Cleavage of F2R at '41-Arg-|-Ser-42' results in receptor activation while cleavage at '55-Phe-|-Trp-56' results in inhibition of receptor activation (PubMed : 7744748). Cleaves the synovial mucin-type protein PRG4/lubricin (PubMed : 32144329). Cleaves and activates IL36G which promotes expression of chemokines CXCL1 and CXLC8 in keratinocytes (PubMed : 30804664). Cleaves IL33 into mature forms which have greater activity than the unprocessed form (PubMed : 22307629). Cleaves coagulation factor F8 to produce a partially activated form (PubMed : 18217133). Also cleaves and activates coagulation factor F10 (PubMed : 8920993). Cleaves leukocyte cell surface protein SPN/CD43 to release its extracellular domain and trigger its intramembrane proteolysis by gamma-secretase, releasing the CD43 cytoplasmic tail chain (CD43-ct) which translocates to the nucleus (PubMed : 18586676). Cleaves CCL5/RANTES to produce RANTES(4-68) lacking the N-terminal three amino acids which exhibits reduced chemotactic and antiviral activities (PubMed : 16963625). During apoptosis, cleaves SMARCA2/BRM to produce a 160 kDa cleavage product which localizes to the cytosol (PubMed : 11259672). Cleaves myelin basic protein MBP in B cell lysosomes at '224-Phe-|-Lys-225' and '248-Phe-|-Ser-249', degrading the major immunogenic MBP epitope and preventing the activation of MBP-specific autoreactive T cells (PubMed : 15100291). Cleaves annexin ANXA1 and antimicrobial peptide CAMP to produce peptides which act on neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed : 22879591). Acts as a ligand for the N-formyl peptide receptor FPR1, enhancing phagocyte chemotaxis (PubMed : 15210802). Has antibacterial activity against the Gram-negative bacteria N.gonorrhoeae and P.aeruginosa (PubMed : 1937776, PubMed : 2116408). Likely to act against N.gonorrhoeae by interacting with N.gonorrhoeae penA/PBP2 (PubMed : 2126324). Exhibits potent antimicrobial activity against the Gram-positive bacterium L.monocytogenes (PubMed : 2117044). Has antibacterial activity against the Gram-positive bacterium S.aureus and degrades S.aureus biofilms, allowing polymorphonuclear leukocytes to penetrate the biofilm and phagocytose bacteria (PubMed : 2117044, PubMed : 32995850). Has antibacterial activity against M.tuberculosis (PubMed : 15385470). Mediates CASP4 activation induced by the Td92 surface protein of the periodontal pathogen T.denticola, causing production and secretion of IL1A and leading to pyroptosis of gingival fibroblasts (PubMed : 29077095). Induces platelet aggregation which is strongly potentiated in the presence of ELANE (PubMed : 25211214, PubMed : 9111081).
See full target information Cathepsin G

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Clinical cancer research : an official journal of 17:2734-43 PubMed21364033

2011

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Applications

WB

Species

Human

Shirin Arastu-Kapur,Janet L Anderl,Marianne Kraus,Francesco Parlati,Kevin D Shenk,Susan J Lee,Tony Muchamuel,Mark K Bennett,Christoph Driessen,Andrew J Ball,Christopher J Kirk

The American journal of pathology 175:207-14 PubMed19528350

2009

Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis.

Applications

WB

Species

Human

Marta Dabek,Laurent Ferrier,Richard Roka,Krisztina Gecse,Anita Annahazi,Jacques Moreau,Jean Escourrou,Christel Cartier,Gilles Chaumaz,Mathilde Leveque,Afifa Ait-Belgnaoui,Tibor Wittmann,Vassilia Theodorou,Lionel Bueno
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com